Cargando…

Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection

Background. For young South African women at risk for human immunodeficiency virus (HIV) infection, preexposure prophylaxis (PrEP) is one of the few effective prevention options available. Long-acting injectable PrEP, which is in development, may be associated with greater adherence, compared with t...

Descripción completa

Detalles Bibliográficos
Autores principales: Walensky, Rochelle P., Jacobsen, Margo M., Bekker, Linda-Gail, Parker, Robert A., Wood, Robin, Resch, Stephen C., Horstman, N. Kaye, Freedberg, Kenneth A., Paltiel, A. David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837902/
https://www.ncbi.nlm.nih.gov/pubmed/26681778
http://dx.doi.org/10.1093/infdis/jiv523
_version_ 1782427925116616704
author Walensky, Rochelle P.
Jacobsen, Margo M.
Bekker, Linda-Gail
Parker, Robert A.
Wood, Robin
Resch, Stephen C.
Horstman, N. Kaye
Freedberg, Kenneth A.
Paltiel, A. David
author_facet Walensky, Rochelle P.
Jacobsen, Margo M.
Bekker, Linda-Gail
Parker, Robert A.
Wood, Robin
Resch, Stephen C.
Horstman, N. Kaye
Freedberg, Kenneth A.
Paltiel, A. David
author_sort Walensky, Rochelle P.
collection PubMed
description Background. For young South African women at risk for human immunodeficiency virus (HIV) infection, preexposure prophylaxis (PrEP) is one of the few effective prevention options available. Long-acting injectable PrEP, which is in development, may be associated with greater adherence, compared with that for existing standard oral PrEP formulations, but its likely clinical benefits and additional costs are unknown. Methods. Using a computer simulation, we compared the following 3 PrEP strategies: no PrEP, standard PrEP (effectiveness, 62%; cost per patient, $150/year), and long-acting PrEP (effectiveness, 75%; cost per patient, $220/year) in South African women at high risk for HIV infection (incidence of HIV infection, 5%/year). We examined the sensitivity of the strategies to changes in key input parameters among several outcome measures, including deaths averted and program cost over a 5-year period; lifetime HIV infection risk, survival rate, and program cost and cost-effectiveness; and budget impact. Results. Compared with no PrEP, standard PrEP and long-acting PrEP cost $580 and $870 more per woman, respectively, and averted 15 and 16 deaths per 1000 women at high risk for infection, respectively, over 5 years. Measured on a lifetime basis, both standard PrEP and long-acting PrEP were cost saving, compared with no PrEP. Compared with standard PrEP, long-acting PrEP was very cost-effective ($150/life-year saved) except under the most pessimistic assumptions. Over 5 years, long-acting PrEP cost $1.6 billion when provided to 50% of eligible women. Conclusions. Currently available standard PrEP is a cost-saving intervention whose delivery should be expanded and optimized. Long-acting PrEP will likely be a very cost-effective improvement over standard PrEP but may require novel financing mechanisms that bring short-term fiscal planning efforts into closer alignment with longer-term societal objectives.
format Online
Article
Text
id pubmed-4837902
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-48379022016-04-21 Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection Walensky, Rochelle P. Jacobsen, Margo M. Bekker, Linda-Gail Parker, Robert A. Wood, Robin Resch, Stephen C. Horstman, N. Kaye Freedberg, Kenneth A. Paltiel, A. David J Infect Dis Major Articles and Brief Reports Background. For young South African women at risk for human immunodeficiency virus (HIV) infection, preexposure prophylaxis (PrEP) is one of the few effective prevention options available. Long-acting injectable PrEP, which is in development, may be associated with greater adherence, compared with that for existing standard oral PrEP formulations, but its likely clinical benefits and additional costs are unknown. Methods. Using a computer simulation, we compared the following 3 PrEP strategies: no PrEP, standard PrEP (effectiveness, 62%; cost per patient, $150/year), and long-acting PrEP (effectiveness, 75%; cost per patient, $220/year) in South African women at high risk for HIV infection (incidence of HIV infection, 5%/year). We examined the sensitivity of the strategies to changes in key input parameters among several outcome measures, including deaths averted and program cost over a 5-year period; lifetime HIV infection risk, survival rate, and program cost and cost-effectiveness; and budget impact. Results. Compared with no PrEP, standard PrEP and long-acting PrEP cost $580 and $870 more per woman, respectively, and averted 15 and 16 deaths per 1000 women at high risk for infection, respectively, over 5 years. Measured on a lifetime basis, both standard PrEP and long-acting PrEP were cost saving, compared with no PrEP. Compared with standard PrEP, long-acting PrEP was very cost-effective ($150/life-year saved) except under the most pessimistic assumptions. Over 5 years, long-acting PrEP cost $1.6 billion when provided to 50% of eligible women. Conclusions. Currently available standard PrEP is a cost-saving intervention whose delivery should be expanded and optimized. Long-acting PrEP will likely be a very cost-effective improvement over standard PrEP but may require novel financing mechanisms that bring short-term fiscal planning efforts into closer alignment with longer-term societal objectives. Oxford University Press 2016-05-15 2015-12-17 /pmc/articles/PMC4837902/ /pubmed/26681778 http://dx.doi.org/10.1093/infdis/jiv523 Text en © The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, contact journals.permissions@oup.com.
spellingShingle Major Articles and Brief Reports
Walensky, Rochelle P.
Jacobsen, Margo M.
Bekker, Linda-Gail
Parker, Robert A.
Wood, Robin
Resch, Stephen C.
Horstman, N. Kaye
Freedberg, Kenneth A.
Paltiel, A. David
Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection
title Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection
title_full Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection
title_fullStr Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection
title_full_unstemmed Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection
title_short Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection
title_sort potential clinical and economic value of long-acting preexposure prophylaxis for south african women at high-risk for hiv infection
topic Major Articles and Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837902/
https://www.ncbi.nlm.nih.gov/pubmed/26681778
http://dx.doi.org/10.1093/infdis/jiv523
work_keys_str_mv AT walenskyrochellep potentialclinicalandeconomicvalueoflongactingpreexposureprophylaxisforsouthafricanwomenathighriskforhivinfection
AT jacobsenmargom potentialclinicalandeconomicvalueoflongactingpreexposureprophylaxisforsouthafricanwomenathighriskforhivinfection
AT bekkerlindagail potentialclinicalandeconomicvalueoflongactingpreexposureprophylaxisforsouthafricanwomenathighriskforhivinfection
AT parkerroberta potentialclinicalandeconomicvalueoflongactingpreexposureprophylaxisforsouthafricanwomenathighriskforhivinfection
AT woodrobin potentialclinicalandeconomicvalueoflongactingpreexposureprophylaxisforsouthafricanwomenathighriskforhivinfection
AT reschstephenc potentialclinicalandeconomicvalueoflongactingpreexposureprophylaxisforsouthafricanwomenathighriskforhivinfection
AT horstmannkaye potentialclinicalandeconomicvalueoflongactingpreexposureprophylaxisforsouthafricanwomenathighriskforhivinfection
AT freedbergkennetha potentialclinicalandeconomicvalueoflongactingpreexposureprophylaxisforsouthafricanwomenathighriskforhivinfection
AT paltieladavid potentialclinicalandeconomicvalueoflongactingpreexposureprophylaxisforsouthafricanwomenathighriskforhivinfection